Company / R&D Expense
Pulmonx Corp R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$17.6M
FY2025
5-year range
$7.5M / $18.1M
FY2021-FY2025
Trend
-2.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $15M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of +20.2%.
Improved from $15M to $18M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +10.4%
- 5-Year CAGR
- +20.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +20.2%, indicating consistent growth.
- In FY2025, r&d expense decreased 2.8% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.6M | -2.8% |
| FY2024 | $18.1M | +17.4% |
| FY2023 | $15.4M | +17.9% |
| FY2022 | $13.1M | +75.1% |
| FY2021 | $7.5M | +6.7% |
| FY2020 | $7.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026